On August 21, 2019, Judge Allison Burroughs of the U.S. District
Court for the District of Massachusetts issued an opinion and order
denying proposed consumer classes in the matter captioned In re
Intuniv Antitrust Litigation. The In re Intuniv Antitrust
Litigation consists of two separate cases, one brought by
direct purchasers of branded and generic Intuniv® (extended
release guanfacine hydrochloride), the other brought by consumers
of the drug (indirect purchasers). In both cases, the plaintiffs
allege that Shire (Takeda) and Actavis (Teva) settled Intuniv
patent litigation via an unlawful pay-for-delay settlement which
the plaintiffs claim delayed competition in brand and generic
Intuniv, resulting in higher prices. The Court denied the Indirect
Purchaser Plaintiffs' Motion for Class Certification. The Court
has not yet issued a ruling on the Direct Purchaser Plaintiffs'
motion.